Combined treatment of rapidly progressing neuroendocrine tumors by transcatheter arterial chemoembolisation of the liver and peptide-receptor radiotherapy is save and effective. Report of thirty consecutive patients
Introduction: Patients with rapidly progressing neuroendocrine tumors presenting with high tumor load and/or severe clinical syndromes are clinically challenging and with limited life expectany. Peptide receptor radiotherapy (PRRT) and transcatheter arterial chemoembolization (TACE) have demonstrated efficacy in the treatment of neuroendocrine tumors. However, there are no reports that both therapies have been applied in combination.
Aim(s): To find out whether a combined treatment of PRRT and TACE is safe and effective.
Materials and methods: We treated thirty consecutive patients (19 male and 11 female, mean age 55.2) years with rapidly progressing neuroendorine tumors with high tumor load or severe functional syndromes by sequential PRRT and TACE.
Conference: 7th Annual ENETSConcerence (2010)
Presenting Author: Hörsch D
To read the full abstract, please log into your ENETS Member account.